Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Equity Average (2016 - 2025)

Historic Equity Average for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to $14.4 million.

  • Marker Therapeutics' Equity Average rose 6836.94% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year increase of 6836.94%. This contributed to the annual value of $16.3 million for FY2024, which is 309.81% down from last year.
  • As of Q3 2025, Marker Therapeutics' Equity Average stood at $14.4 million, which was up 6836.94% from $12.5 million recorded in Q2 2025.
  • In the past 5 years, Marker Therapeutics' Equity Average ranged from a high of $67.9 million in Q2 2021 and a low of $8.6 million during Q3 2024
  • Its 5-year average for Equity Average is $26.3 million, with a median of $17.8 million in 2023.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 8340.67% in 2021, then crashed by 5617.58% in 2022.
  • Quarter analysis of 5 years shows Marker Therapeutics' Equity Average stood at $48.1 million in 2021, then plummeted by 56.16% to $21.1 million in 2022, then dropped by 27.11% to $15.4 million in 2023, then dropped by 15.45% to $13.0 million in 2024, then grew by 11.04% to $14.4 million in 2025.
  • Its Equity Average was $14.4 million in Q3 2025, compared to $12.5 million in Q2 2025 and $16.5 million in Q1 2025.